Cargando…

Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis

INTRODUCTION: Evidence suggests a potentially causal role of interleukin 6 (IL-6), a pleiotropic cytokine that generally promotes inflammation, in the pathogenesis of psychosis. However, no interventional studies in patients with psychosis, stratified using inflammatory markers, have been conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foley, Éimear M, Griffiths, Sian Lowri, Murray, Alexander, Rogers, Jack, Corsi-Zuelli, Fabiana, Hickinbotham, Hannah, Warwick, Ella, Wilson, Martin, Kaser, Muzaffer, Murray, Graham K, Deakin, Bill, Jadon, Deepak, Suckling, John, Barnes, Nicholas M, Upthegrove, Rachel, Khandaker, Golam M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040013/ https://www.ncbi.nlm.nih.gov/pubmed/36963796 http://dx.doi.org/10.1136/bmjopen-2022-067944

Ejemplares similares

T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives
por: Corsi-Zuelli, Fabiana, et al.
Publicado: (2021)

Recognition and management of depression in early psychosis
por: Bashir, Zainab, et al.
Publicado: (2022)

Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation
por: Khandaker, Golam M, et al.
Publicado: (2018)

Neurocognitive Performance in Depressed Patients with low-grade inflammation and somatic symptoms
por: Kaser, Muzaffer, et al.
Publicado: (2021)

A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis
por: Chaudhry, I. B., et al.
Publicado: (2020)

Dysglycaemia, Inflammation and Psychosis: Findings From the UK ALSPAC Birth Cohort
por: Perry, Benjamin Ian, et al.
Publicado: (2019)

Correction: A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis
por: Chaudhry, I. B., et al.
Publicado: (2021)

Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis
por: Perry, Benjamin I, et al.
Publicado: (2021)

Immune regulatory gene polymorphisms, frequent cannabis use, and psychosis: implications to Treg hypofunction
por: Corsi-Zuelli, F., et al.
Publicado: (2022)

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial
por: Lisiecka, Danuta M, et al.
Publicado: (2015)

Predicting treatment resistance in people with a first-episode of psychosis using commonly recorded clinical information
por: Osimo, E.F., et al.
Publicado: (2022)

Predicting treatment resistance from first-episode psychosis using routinely collected clinical information
por: Osimo, Emanuele F., et al.
Publicado: (2023)

Heterogeneity in treatment outcomes and incomplete recovery in first episode psychosis: does one size fit all?
por: Griffiths, Siân Lowri, et al.
Publicado: (2022)

Longitudinal Trends in Childhood Insulin Levels and Body Mass Index and Associations With Risks of Psychosis and Depression in Young Adults
por: Perry, Benjamin I., et al.
Publicado: (2021)

30.1 IMMUNE PATHOGENESIS OF PSYCHOSIS: THE CHALLENGE OF CO-MORBIDITY
por: Upthegrove, Rachel, et al.
Publicado: (2018)

Voxel-based morphometric imaging in first-episode psychosis: interrogating the role of familial liability
por: Corsi-Zuelli, F. C., et al.
Publicado: (2023)

Environmental risk factors for psychosis
por: Dean, Kimberlie, et al.
Publicado: (2005)

Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
por: Parkinson, Joel T., et al.
Publicado: (2020)

30. AN IMMUNE PATHOGENESIS OF PSYCHOSIS? EVIDENCE AND CHALLENGES FROM BENCH TO BEDSIDE
por: Upthegrove, Rachel
Publicado: (2018)

The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial
por: Deakin, Bill, et al.
Publicado: (2018)

Assessment of the Role of IQ in Associations Between Population Density and Deprivation and Nonaffective Psychosis
por: Lewis, Gemma, et al.
Publicado: (2020)

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis
por: Shields, Gemma E., et al.
Publicado: (2022)

The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
por: Perry, Benjamin I., et al.
Publicado: (2022)

F23. LOW-GRADE INFLAMMATORY PROFILE IN FIRST-EPISODE PSYCHOSIS: RESULTS FROM THE STREAM STUDY IN BRAZIL
por: Corsi-Zuelli, Fabiana, et al.
Publicado: (2018)

T86. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS: AN EMPIRICAL LONGITUDINAL STUDY OF RELATIONSHIP TO COGNITIVE, SYMPTOM AND FUNCTIONAL OUTCOMES
por: Watson, Andrew, et al.
Publicado: (2018)

Health beliefs and carer burden in first episode psychosis
por: Patel, Maya, et al.
Publicado: (2014)

Structure and stability of symptoms in first episode psychosis: a longitudinal network approach
por: Griffiths, Siân Lowri, et al.
Publicado: (2021)

Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort
por: Khandaker, Golam M., et al.
Publicado: (2018)

Childhood inflammatory markers and risks for psychosis and depression at age 24: Examination of temporality and specificity of association in a population-based prospective birth cohort
por: Perry, Benjamin I., et al.
Publicado: (2021)

An International External Validation and Revision of the PsyMetRiC Cardiometabolic Risk Prediction Algorithm for Young People with Psychosis
por: Perry, B., et al.
Publicado: (2022)

O9.3. CANNABIS CONSUMPTION INCREASES RISK OF PSYCHOSIS IN A SUBGROUP OF PATIENTS WITH HIGH PERIPHERAL BLOOD INFLAMMATION
por: Corsi-Zuelli, Fabiana, et al.
Publicado: (2020)

T26. PERINATAL STRESS AND PSYCHOSIS: RESULTS FROM THE BOLOGNA FIRST EPISODE PSYCHOSIS (BO-FEP) STUDY
por: Tarricone, Ilaria, et al.
Publicado: (2018)

Inflammatory and cardiometabolic markers at presentation with first episode psychosis and long-term clinical outcomes: A longitudinal study using electronic health records
por: Osimo, Emanuele F., et al.
Publicado: (2021)

The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis
por: Schwarzer, Johanna M., et al.
Publicado: (2022)

Common mechanisms for type 2 diabetes and psychosis: Findings from a prospective birth cohort
por: Perry, Benjamin I., et al.
Publicado: (2020)

Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort
por: Khandaker, Golam M., et al.
Publicado: (2021)

Searching for psychosis: INTREPID (1): systems for detecting untreated and first-episode cases of psychosis in diverse settings
por: Morgan, Craig, et al.
Publicado: (2015)

The Maudsley environmental risk score for psychosis
por: Vassos, Evangelos, et al.
Publicado: (2020)

Psychosis risk syndrome is not prodromal psychosis
por: XU, Lihua, et al.
Publicado: (2015)

Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial
por: Palmer, Edward R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q30skvbkbee153hbi84hf4o7d8